INO

Inovio Pharmaceuticals Inc

INO, USA

Inovio Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids. Its products in pipeline include VGX-3100 for the treatment of HPV-related cervical high-grade dysplasia; INO-3107 for HPV-related recurrent respiratory papillomatosis and is under Phase 1/2 trial; INO-3112 for the treatment of HPV-related Oropharyngeal Squamous Cell Carcinoma and is under Phase 2 trial; INO-5401 for the treatment of glioblastoma multiforme and is under Phase 2 trial; INO-4201 for Ebola Virus Disease and is under Phase 1b trial; INO-4800 for COVID-19 and is under Phase 3 trial; and INO-6160 for the treatment of human immunodeficiency virus and is under Phase 1 trial. Its partners and collaborators include Advaccine Biopharmaceuticals Suzhou Co, ApolloBio Corporation, AstraZeneca, The Bill & Melinda Gates Foundation, Coalition for Epidemic Preparedness Innovations, Defense Advanced Research Projects Agency, The U.S. Department of Defense, HIV Vaccines Trial Network, International Vaccine Institute, Kaneka Eurogentec, National Cancer Institute, National Institutes of Health, National Institute of Allergy and Infectious Diseases, the University of Pennsylvania, Plumbline Life Sciences, Regeneron Pharmaceuticals, Richter BioLogics, the Walter Reed Army Institute of Research, and The Wistar Institute. The company was incorporated in 1983 and is headquartered in Plymouth Meeting, Pennsylvania.

https://www.inovio.com

Stock Price

$0.00

0%

decrease compared to yesterday.

Dividend

Frequency:

N/A

Rate:

N/A

Next Payout:

N/A
INO
stock
INO

*CORRECTION*INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Inovio Pharmaceuticals, Inc. - INO PR Newswire

Read more →
INO
stock
INO

Inovio Pharmaceuticals: Speculative Buy Thesis Hinges On INO-3107 (NASDAQ:INO) Seeking Alpha

Read more →

Showing 2 of 10

Analyst Ratings & Sentiment

(Last Updated 2025-09-30)

Rating:

BUY

Target Price:

$7.6333

Analyst Picks

Strong Buy

2

Buy

1

Hold

2

Sell

0

Strong Sell

0

Sentiment:

Bullish

Finn Analysis

(Last Updated 2025-09-30)

Health Score

Price to Book Ratio (P/B)

-

Very Low

-10.61

Low ≤ 1

High ≥ 3

Return on Equity (ROE)

-

Very High

589.34 %

Low ≤ 5%

High ≥ 25%

Return on Assets (ROA)

-

Very Low

-65.57 %

Low ≤ 2%

High ≥ 10%

Investors

* Institutions hold a combined 23.12% of the total shares of Inovio Pharmaceuticals Inc

1.

Vanguard Group Inc

(3.7807%)

since

2025/06/30

2.

Deep Track Capital, LP

(3.7284%)

since

2025/06/30

3.

Vanguard Total Stock Mkt Idx Inv

(3.0169%)

since

2025/07/31

4.

Bank of America Corp

(2.3909%)

since

2025/06/30

5.

BlackRock Inc

(1.0117%)

since

2025/06/30

6.

Geode Capital Management, LLC

(0.8233%)

since

2025/06/30

7.

Morgan Stanley - Brokerage Accounts

(0.7562%)

since

2025/06/30

8.

Vanguard Institutional Extnd Mkt Idx Tr

(0.7069%)

since

2025/07/31

9.

Millennium Management LLC

(0.6527%)

since

2025/06/30

10.

Renaissance Technologies Corp

(0.6174%)

since

2025/06/30

11.

Northern Trust Corp

(0.4788%)

since

2025/06/30

12.

Vanguard Strategic Equity Inv

(0.4707%)

since

2025/06/30

13.

UBS Group AG

(0.3757%)

since

2025/06/30

14.

Fidelity Extended Market Index

(0.3675%)

since

2025/07/31

15.

Cubist Systematic Strategies, LLC

(0.3228%)

since

2025/06/30

16.

Citadel Advisors Llc

(0.3179%)

since

2025/06/30

17.

GSA Capital Partners LLP

(0.3072%)

since

2025/06/30

18.

Susquehanna International Group, LLP

(0.2846%)

since

2025/06/30

19.

Goldman Sachs Group Inc

(0.2574%)

since

2025/06/30

20.

GMT Capital Corp

(0.2373%)

since

2025/06/30

21.

State Street Corp

(0.2326%)

since

2025/06/30

22.

Royal Bank of Canada

(0.2301%)

since

2025/06/30

23.

Qube Research & Technologies

(0.2167%)

since

2025/06/30

24.

FMR Inc

(0.1644%)

since

2025/06/30

25.

iShares Micro-Cap ETF

(0.1524%)

since

2025/08/31

26.

Fidelity Nasdaq Composite Index

(0.1471%)

since

2025/07/31

27.

Extended Equity Market Fund K

(0.1102%)

since

2025/06/30

28.

Northern Small Cap Core I

(0.0995%)

since

2025/06/30

29.

Fidelity Series Total Market Index

(0.0987%)

since

2025/07/31

30.

Fidelity Total Market Index

(0.0887%)

since

2025/07/31

31.

Vanguard Strategic Small-Cap Equity Inv

(0.0874%)

since

2025/06/30

32.

Spartan Extended Market Index Pool F

(0.0807%)

since

2025/07/31

33.

Northern Trust Extended Eq Market Idx

(0.0782%)

since

2025/06/30

34.

NT Ext Equity Mkt Idx Fd - L

(0.0782%)

since

2025/06/30

35.

NT Col R2000 Val Idx Fd -DC -L -TierFour

(0.0751%)

since

2025/03/31

36.

NT Ext Equity Mkt Idx Fd - NL

(0.0654%)

since

2025/06/30

37.

Vanguard Balanced Index Inv

(0.058%)

since

2025/07/31

38.

NT Ext Equity Mkt Idx Fd - DC - NL - T2

(0.0508%)

since

2025/06/30

39.

NT Quality SCC US Fund - L

(0.05%)

since

2025/06/30

40.

NT Quality Small Cap Core

(0.05%)

since

2025/06/30

* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.

Earnings History

EPS ActualEPS EstimateEPS DifferenceSurprise Percent

Upcoming Earnings Release

Date

—

EPS Estimate

—

Latest Release

Date

2025-09-30

EPS Actual

-0.87

EPS Estimate

-0.99

EPS Difference

0.12

Surprise Percent

12.1212%

Investing Fit Scorecard

(Last Updated 2025-09-30)

Deep Value
Weak Deep Value(1.5)
Defensive
Highly Defensive(7)
Dividend
Weak Dividend Profile(1.5)
Economic Moat
Some Competitive Advantage(5.3)
GARP
Not Attractive for GARP(2)
Growth
Weak Growth Prospect(2)
Momentum
No Momentum(2.5)
Net Net
Not Undervalued (Net-Net)(1)
Quality
Low Quality Business(2.5)
Value
Overpriced(2.5)

Income Statement

(Last Updated 2025-09-30)

Revenue

$ 0

Cost Of Revenue

$ 0

Gross Profit

$ 0

Operating Expenses

$ 0

Operating Income

$ 0

Interest Expense

$ 0

Pretax Income

$ 0

Net Income

$ 0

Income Tax Expense

$ 0

EBITDA

$ 0

Total Other Income Expense Net

$ 0

Earnings Per Share

0

Dividends Per Share

0

Shares Outstanding

0

Operating Margin

0%

Trend

Balance Sheet

(Last Updated 2025-09-30)

Cash

$ 0

Short Term Investments

$ 0

Receivables

$ 0

Inventories

$ 0

Total Current Assets

$ 0

Property Plant Equipment

$ 0

Total Assets

$ 0

Payables

$ 0

Short Term Debt

$ 0

Long Term Debt

$ 0

Total Liabilities

$ 0

Equity

$ 0

Trend

Cash Flow

(Last Updated 2025-09-30)

Net Income

$ 0

Depreciation

$ 0

Change In Working Capital

$ 0

Cash From Operations

$ 0

Capital Expenditures

$ 0

Cash From Investing

$ 0

Cash From Financing

$ 0

Net Change In Cash

$ 0

Trend

Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.